Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice

Neurochemistry International

Volumn 99, Issue , 2016, Pages 221-232

  Singh, Alpana ^a   Verma, Poonam ^a   Balaji, Gillela ^a   Samantaray, Supriti ^b   Mohanakumar, Kochupurackal P ^a,c  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MAHATMA GANDHI UNIVERSITY   (India)

Author keywords

Dopaminergic neuroprotection; Intracellular calcium levels; Mitochondrial membrane potential; Motor functions in mice; SH SY5Y cell line

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALCIUM CHANNEL; NIMODIPINE; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; NEUROPROTECTIVE AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; CYTOSOL; DOSE RESPONSE; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; MPTP-INDUCED PARKINSONISM; MTT ASSAY; NERVE CELL; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; INTOXICATION; METABOLISM; PARKINSON DISEASE; PHYSIOLOGY; TUMOR CELL LINE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; MICE; MICE, INBRED BALB C; MITOCHONDRIA; MPTP POISONING; NEUROPROTECTIVE AGENTS; NIMODIPINE; PARKINSON DISEASE, SECONDARY; REACTIVE OXYGEN SPECIES;

EID: 84984792001     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2016.07.003     Document Type: Article

References (85)

1. Agid, Y., Parkinson's disease: pathophysiology. Lancet 337:8753 (1991), p1321–1324.
2. Ankarcrona, M., Dypbukt, J.M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S.A., Nicotera, P., Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15:4 (1995), 961–973.
3. Antony, A.S., Vadivelan, R., Kumar, M.N.S., Elango, K., Vijayan, P., Evaluation of nimodipine, amlodipine and nitrendipine for anti-parkinson's activity in 6-OHDA lesioned parkinson's rat model. J. Pharm. Res. 5:12 (2012), 5470–5473.
4. Appukuttan, T.A., Varghese, M., Ali, N., Singh, A., Tripathy, D., Padmakumar, M., Gangopadhyay, P.K., Mohanakumar, K.P., Parkinson's disease cybrids, differentiated or undifferentiated, maintain distinct morphological and biochemical phenotypes different from the control cybrids. J. Neurosci. Res. 91 (2013), 963–970.
5. + in Sprague-Dawley rats: cellular, molecular and ultrastructural evidences. Neurochem. Res. 32:7 (2007), 1238–1247.
6. Banerjee, R., Starkov, A.A., Beal, M.F., Thomas, B., Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 1792:7 (2009), 651–663.
7. Becker, C., Jick, S.S., Meier, C.R., Use of antihypertensives and the risk of Parkinson disease. Neurology 70:16 (2008), 1438–1444.
8. Birkmayer, W., Hornykiewicz, O., The L-3,4-dioxyphenylalanine (DOPA)-effect in parkinson-akinesia. Wien. Klin. Wochenschr 73 (1961), 787–788.
9. Borland, M.K., Trimmer, P.A., Rubinstein, J.D., Keeney, P.M., Mohanakumar, K., Liu, L., Bennett, J.P. Jr., Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol. Neurodegener., 3, 2008, 21.
10. 2+ buffers and synaptic efficacy. Cell Calcium 37:5 (2005), 489–495.
11. Calvaruso, M.A., Willems, P., van den Brand, M., Valsecchi, F., Kruse, S., Palmiter, R., Smeitink, J., Nijtmans, L., Mitochondrial complex III stabilizes complex I in the absence of NDUFS4 to provide partial activity. Hum. Mol. Genet. 21 (2012), 115–120.
12. Chan, C.S., Guzman, J.N., Ilijic, E., Mercer, J.N., Rick, C., Tkatch, T., Meredith, G.E., Surmeier, D.J., Rejuvenation protects neurons in mouse models of Parkinson's disease. Nature 447:7148 (2007), 1081–1086.
13. Cheung, Y.T., Lau, W.K., Yu, M.S., Lai, C.S., Yeung, S.C., So, K.F., Chang, R.C., Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30:1 (2009), 127–135.
14. Choi, W.S., Kruse, S.E., Palmiter, R.D., Xia, Z., Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 15136–15141.
15. Chu, C.T., Ji, J., Dagda, R.K., Jiang, J.F., Tyurina, Y.Y., Kapralov, A.A., Tyurin, V.A., Yanamala, N., Shrivastava, I.H., Mohammadyani, D., Qiang Wang, K.Z., Zhu, J., Klein-Seetharaman, J., Balasubramanian, K., Amoscato, A.A., Borisenko, G., Huang, Z., Gusdon, A.M., Cheikhi, A., Steer, E.K., Wang, R., Baty, C., Watkins, S., Bahar, I., Bayır, H., Kagan, V.E., Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell Biol. 15:10 (2013), 1197–1205.
16. Daschil, N., Humpel, C., Nifedipine and nimodipine protect dopaminergic substantia nigra neurons against axotomy-induced cell death in rat vibrosections via modulating inflammatory responses. Brain Res. 1581 (2014), 1–11.
17. Dauer, W., Przedborski, S., Parkinson's disease: mechanisms and models. Neuron 39:6 (2003), 889–909.
18. +-induced cell death. J. Neurochem. 125:3 (2013), 473–485.
19. Double, K.L., Reyes, S., Werry, E.L., Halliday, G.M., Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions?. Prog. Neurobiol. 92:3 (2010), 316–329.
20. Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., Marshall, F.J., Ravina, B.M., Schifitto, G., Siderowf, A., Tanner, C.M., Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:5 (2007), 384–386.
21. Estabrook, R.W., Mitochondrial respiratory control and polarographic measurement of ADP: O ratios. Methods Enzymol. 10 (1967), 41–47.
22. Fiesel, F.C., Caulfield, T.R., Moussaud-Lamodière, E.L., Dourado, K.O., Flores, S.C., Ross, O.A., Springer, W., Structural and functional impact of parkinson disease-associated mutations in the E3 ubiquitin ligase parkin. Hum. Mutat. 36:8 (2015), 774–786.
23. German, D.C., Manaye, K.F., Sonsalla, P.K., Brooks, B.A., Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. N. Y. Acad. Sci. 648 (1992), 42–62.
24. Grace, A.A., Bunney, B.S., The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci. 4:11 (1984), 2866–2876.
25. Groden, D.L., Guan, Z., Stokes, B.T., Determination of Fura-2 dissociation constants following adjustment of the apparent Ca-EGTA association constant for temperature and ionic strength. Cell Calcium 12:4 (1991), 279–287.
26. Grynkiewicz, G., Poenie, M., Tsien, R.Y., A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260 (1985), 3440–3449.
27. Haobam, R., Sindhu, K.M., Chandra, G., Mohanakumar, K.P., Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Behav. Brain Res. 163:2 (2005), 159–167.
28. Haobam, R., Tripathy, D., Kaidery, N.A., Mohanakumar, K.P., Embryonic stem cells derived neuron transplantation recovery in models of parkinsonism in relation to severity of the disorder in rats. Rejuvenation Res. 18:2 (2015), 173–184.
29. 2+ signaling in Purkinje neurons. Cell Calcium 37:5 (2005), 459–466.
30. Hu, Y., Li, J., Liu, P., Chen, X., Guo, D.H., Li, Q.S., Rahman, K., Protection of SH-SY5Y neuronal cells from glutamate-induced apoptosis by 3,6’-disinapoyl sucrose, a bioactive compound isolated from Radix Polygala. J. Biomed. Biotechnol., 2012, 1–5.
31. Ibáñez-Sandoval, O., Tecuapetla, F., Unal, B., Shah, F., Koós, T., Tepper, J.M., Electrophysiological and morphological characteristics and synaptic connectivity of tyrosine hydroxylase-expressing neurons in adult mouse striatum. J. Neurosci. 30:20 (2010), 6999–7016.
32. Ilijic, E., Guzman, J.N., Surmeier, D.J., The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 43:2 (2011), 364–371.
33. Im, E., Chung, K.C., Dyrk1A Phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity. J. Neurochem. 134:4 (2015), 756–768.
34. Justin, A., Sathishkumar, M., Sudheer, A., Shanthakumari, S., Ramanathan, M., Non-hypotensive dose of telmisartan and nimodipine produced synergistic neuroprotective effect in cerebral ischemic model by attenuating brain cytokine levels. Pharmacol. Biochem. Behav. 122 (2014), 61–73.
35. Karuppagounder, S.S., Madathil, S.K., Pandey, M., Haobam, R., Rajamma, U., Mohanakumar, K.P., Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats. Neuroscience 236 (2013), 136–148.
36. Kaygisiz, B., Ozatik, F.Y., Erol, K., Interaction of sertraline and nimodipine on some behavioural tests in rats. Adv. Clin. Exp. Med. 23:2 (2014), 169–175.
37. Kazlauskaite, A., Muqit, M.M., PINK1 and Parkin: mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease. FEBS J. 282:2 (2015), 215–223.
38. Keeney, P.M., Xie, J., Capaldi, R.A., Bennett, J.P. Jr., Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26:19 (2006), 5256–5264.
39. Kim, H.W., Choi, W.S., Sorscher, N., Park, H.J., Tronche, F., Palmiter, R.D., Xia, Z., Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo. Neurobiol. Aging 36:9 (2015), 2617–2627.
40. Kinnally, K.W., Peixoto, P.M., Ryu, S.Y., Dejean, L.M., Is mPTP the gatekeeper for necrosis, apoptosis, or both?. Biochim. Biophys. Acta 1813:4 (2011), 616–622.
41. Kupsch, A., Gerlach, M., Pupeter, S.C., Sautter, J., Dirr, A., Arnold, G., Opitz, W., Przuntek, H., Riederer, P., Oertel, W.H., Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 6:4 (1995), 621–625.
42. Kupsch, A., Sautter, J., Schwarz, J., Riederer, P., Gerlach, M., Oertel, W.H., 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 741:1–2 (1996), 185–196.
43. Lafon-Cazal, M., Pietri, S., Culcasi, M., Bockaert, J., NMDA-dependent superoxide production and neurotoxicity. Nature 364:6437 (1993), 535–537.
44. Lindvall, O., Developing dopaminergic cell therapy for Parkinson's disease - give up or move forward?. Mov. Disord. 28:3 (2013), 268–273.
45. Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1 (1951), 265–275.
46. Luo, J., Shi, R., Acrolein induces oxidative stress in brain mitochondria. Neurochem. Int. 46:3 (2005), 243–252.
47. Mann, V.M., Cooper, J.M., Daniel, S.E., Srai, K., Jenner, P., Marsden, C.D., Schapira, A.H., Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36:6 (1994), 876–881.
48. Martins, J.B., Bastos, MdeL., Carvalho, F., Capela, J.P., Differential effects of methyl-4-phenylpyridinium ion, rotenone, and paraquat on differentiated SH-SY5Y cells. J. Toxicol., 2013, 2013, 347312.
49. Mattson, M.P., Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med. 3:2 (2003), 65–94.
50. Mendez, J.A., Bourque, M.-J., Fasano, C., Kortleven, C., Trudeau, L.-E., Somatodendritic dopamine release requires synaptotagmin 4 and 7 and the participation of voltage-gated calcium channels. J. Biol. Chem. 286:27 (2011), 23928–23937.
51. Mercuri, N.B., Bonci, A., Calabresi, P., Stratta, F., Stefani, A., Bernardi, G., Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br. J. Pharmacol. 113:3 (1994), 831–838.
52. Mitra, N., Mohanakumar, K.P., Ganguly, D.K., Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase-B. J. Neurochem. 62 (1994), 1906–1912.
53. Mohanakumar, K.P., Samantaray, S., Büsselberg, B., The parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on membrane currents and intrasynaptosomal calcium. Neurosci. Res. Commn 30:1 (2002), 35–42.
54. Morinan, A., Garratt, H.M., An improved fluorimetric assay for brain monoamine oxidase. J. Pharmacol. Methods 13 (1985), 213–223.
55. Mosharov, E.V., Larsen, K.E., Kanter, E., Phillips, K.A., Wilson, K., Schmitz, Y., Krantz, D.E., Kobayashi, K., Edwards, R.H., Sulzer, D., Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 62:2 (2009), 218–229.
56. Muralikrishnan, D., Mohanakumar, K.P., Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice. FASEB J. 12:10 (1998), 905–912.
57. Naskar, A., Manivasagam, T., Chakraborty, J., Singh, R., Thomas, B., Dhanasekaran, M., Mohanakumar, K.P., Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J. Pineal Res. 55:3 (2013), 304–312.
58. Naskar, A., Prabhakar, V., Singh, R., Dutta, D., Mohanakumar, K.P., Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose and protects dopaminergic neurons in MPTP-induced parkinsonism in mice. J. Pineal Res. 58 (2015), 262–274.
59. Nataraj, J., Manivasagam, T., Justin Thenmozhi, A., Essa, M.M., Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress. Nutr. Neurosci., 2015, 10.1179/1476830515Y.0000000010.
60. 2+ conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol. 466 (1993), 727–747.
61. Pandey, M., Varghese, M., Sindhu, K.M., Sreetama, S., Navneet, A.K., Mohanakumar, K.P., Usha, R., Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J. Neurochem. 104:2 (2008), 420–434.
62. Parsanejad, M., Bourquard, N., Qu, D., Zhang, Y., Huang, E., Rousseaux, M.W., Aleyasin, H., Irrcher, I., Callaghan, S., Vaillant, D.C., Kim, R.H., Slack, R.S., Mak, T.W., Reddy, S.T., Figeys, D., Park, D.S., DJ-1 interacts with and regulates paraoxonase-2, an enzyme critical for neuronal survival in response to oxidative stress. PLoS One, 9(9), 2014, e106601.
63. Pasternak, B., Svanström, H., Nielsen, N.M., Fugger, L., Melbye, M., Hviid, A., Use of calcium channel blockers and Parkinson's disease. Am. J. Epidemiol. 175:7 (2012), 627–635.
64. Puopolo, M., Raviola, E., Bean, B.P., Roles of sub-threshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci. 27:3 (2007), 645–656.
65. Rio, M.J., Velez-Pardo, C., Paraquat induces apoptosis in human lymphocytes: protective and rescue effects of glucose, cannabinoids and insulin-like growth factor-1. Growth Factors 26:1 (2008), 49–60.
66. Rivero-Ríos, P., Gómez-Suaga, P., Fdez, E., Hilfiker, S., Upstream deregulation of calcium signaling in Parkinson's disease. Front. Mol. Neurosci., 7, 2014, 53.
67. Ritz, B., Rhodes, S.L., Qian, L., Schernhammer, E., Olsen, J.H., Friis, S., L-type calcium channel blockers and parkinson disease in Denmark. Ann. Neurol. 67:5 (2010), 600–606.
68. Rodriguezy Baena, R., Gaetani, P., Silvani, V., Spanu, G., Marzatico, F., Effect of nimodipine on mitochondrial respiration in different rat brain areas after subarachnoid haemorrhage. Acta Neurochir. Suppl. (Wien) 43 (1988), 177–181.
69. Ryan, S.D., Dolatabadi, N., Chan, S.F., Zhang, X., Akhtar, M.W., Parker, J., Soldner, F., Sunico, C.R., Nagar, S., Talantova, M., Lee, B., Lopez, K., Nutter, A., Shan, B., Molokanova, E., Zhang, Y., Han, X., Nakamura, T., Masliah, E., Yates, J.R., Nakanishi, N., Andreyev, A.Y., Okamoto, S., Jaenisch, R., Ambasudhan, R., Lipton, S.A., Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell 155:6 (2013), 1351–1364.
70. Saravanan, K.S., Sindhu, K.M., Mohanakumar, K.P., Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res. 1049:2 (2005), 147–155.
71. Sautter, J., Kupsch, A., Earl, C.D., Oertel, W.H., Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine. Exp. Brain Res. 117:1 (1997), 111–119.
72. Sen, A.P., Boksa, P., Quirion, R., Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases. Brain Res. 611:2 (1993), 216–221.
73. Sengupta, T., Mohanakumar, K.P., 2-Phenylethylamine, a constituent of chocolate and wine, causes mitochondrial complex-I inhibition, generation of hydroxyl radicals and depletion of striatal biogenic amines leading to psycho-motor dysfunctions in Balb/c mice. Neurochem. Int. 57:6 (2010), 637–646.
74. Sheehan, J.P., Swerdlow, R.H., Parker, W.D., Miller, S.W., Davis, R.E., Tuttle, J.B., Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68:3 (1997), 1221–1233.
75. Surmeier, D.J., Guzman, J.N., Sanchez-Padilla, J., Schumacker, P.T., The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta. Neuroscience 198 (2011), 221–231.
76. Tintner, R., Jankovic, J., Treatment options for Parkinson's disease. Curr. Opin. Neurol. 15:4 (2002), 467–476.
77. Thomas, B., Muralikrishnan, D., Mohanakumar, K.P., In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. 852:1 (2000), 221–224.
78. Tripathy, D., Haobam, R., Nair, R., Mohanakumar, K.P., Engraftment of mouse embryonic stem cells differentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats. PLoS One, 8(9), 2013, e72501.
79. Tripathy, D., Verma, P., Nthenge-Ngumbau, D.N., Banerjee, M., Mohanakumar, K.P., Regenerative therapy in experimental parkinsonism: mixed population of differentiated mouse embryonic stem cells, rather than magnetically sorted and enriched dopaminergic cells provide neuroprotection. CNS Neurosci. Ther. 20:8 (2014), 717–727.
80. Trudler, D., Nash, Y., Frenkel, D., New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation. J. Neural. Transm., 2015, 10.1007/s00702-015-1399-z.
81. Varghese, M., Pandey, M., Samanta, A., Gangopadhyay, P.K., Mohanakumar, K.P., Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population. J. Neurol. Sci. 279:1–2 (2009), 39–42.
82. Weihmuller, F.B., Hadjiconstantinou, M., Bruno, J.P., Acute stress or neuroleptics elicit sensorimotor deficits in MPTP treated mice. Neurosci. Lett. 85:1 (1988), 137–142.
83. Weihmuller, F.B., Hadjiconstantinou, M., Bruno, J.P., Dissociation between biochemical and behavioral recovery in MPTP-treated mice. Pharmacol. Biochem. Behav. 34:1 (1989), 113–117.
84. Yamada, T., McGeer, P.L., Baimbridge, K.G., McGeer, E.G., Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 526:2 (1990), 303–307.
85. Yuste, R., Majewska, A., Holthoff, K., From form to function: calcium compartmentalization in dendritic spines. Nat. Neurosci. 3:7 (2000), 653–659.